Navigation Links
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications Department determined, using its discretionary authority under Nasdaq Marketplace Rule 4300, that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq. The Letter further stated that Nasdaq would suspend trading in the Company's ADRs at the opening of trading on February 5, 2009 and then file a Form 25-NSE with the Securities and Exchange Commission ("SEC") to deregister the Company's ADRs, unless the Company appeals Nasdaq's delisting determination. Nasdaq's determination to delist the ADRs was based on Nasdaq's belief that the Company was a public shell and that the Company does not meet the stockholder's equity requirement or any of its alternatives.

The Letter also indicated that, in accordance with the procedures set out in Marketplace Rule 4800 Series, the Company would have seven (7) calendar days, or until February 3, 2009, to appeal the delisting from Nasdaq to a Listing Qualifications Panel. At this time, the Company does plan to appeal the delisting from Nasdaq. There can be no assurance that the appeal will be successful.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Hyman Jr. Professor of Chemistry, was recently awarded ... the synthesis of a wide range of nanoscale ... of those materials, and the development of hierarchical ... the use of nanoscale materials in nanoelectronics, nanocomputing, ...
... Mich., Jan. 23, 2012  A recent Van Andel Research Institute ... the molecular structure and function of an essential plant hormone ... and might ultimately lead to the development of new drugs ... builds on earlier work by the same team of investigators ...
... 23, 2012 Aethlon Medical, Inc. ... filtration devices to address infectious disease, cancer and ... established an Extracorporeal Therapy Scientific Advisory Board to ... other therapies developed from the Aethlon ADAPT™ system.  ...
Cached Biology Technology:Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... to diagnose infectious diseases are urgently needed in ... an American Academy of Microbiology colloquium, "Bringing the ... Resource Limited Settings," describes the challenges inherent in ... areas of the world where they are needed ...
... (SACRAMENTO, Calif.) A team of UC Davis investigators has ... in the development of prostate cancer. The mutation of the ... disease progression, but until now has never been shown to ... avenues for diagnosing and treating the disease. The ...
... As one of the few probiotics with medical food ... a collection of more than 80 studies that have demonstrated ... and an ileal pouch. Ulcerative colitis patients, in particular, have ... their prescription drug regimen. One particular study shows that the ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
...
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: